The Effect of Leflunomide on Cycling and Activation of T-Cells in HIV-1-Infected Participants
Sarah W. Read, Mary DeGrezia, Emily J. Ciccone et al. · 2010
Read The Effect of Leflunomide on Cycling and Activation of T-Cells in HIV-1-Infected Participants by Sarah W. Read, Mary DeGrezia, Emily J. Ciccone et al. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0011937.txt.
Description
Sarah Read and co-workers tested in 2010 whether an arthritis drug could calm the immune overdrive seen in HIV infection. Even when HIV is controlled, constant immune activation helps drive the disease. Leflunomide, a drug that tempers immune cell growth, was a candidate for lowering that activation.
In a randomized study of HIV-1 infected participants, the team measured how the drug affected T cell cycling and activation. Slowing the churn of T cells could, in principle, reduce the damage activation causes over years. The trial gives an early read on whether repurposing an existing immune drug is a safe and sensible path in HIV care.
Catalog record
| CREATOR | Sarah W. Read, Mary DeGrezia, Emily J. Ciccone et al. |
|---|---|
| YEAR | 2010 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| LICENSE | Creative Commons CC0 License |
| RIGHTS | CC0 |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0011937